medigraphic.com
ISSN 0016-3813 (Print)

2014, Number s1

<< Back Next >>

Gac Med Mex 2014; 150 (s1)

The Mexican Registry of Atrial Fibrillation (ReMeFa)

Lara-Vaca S, Cordero-Cabra A, Martínez-Flores E, Iturralde-Torres P

Language: Spanish
References: 26
Page: 48-59
PDF size: 306.87 Kb.


ABSTRACT

Introduction: The Mexican Registry of Atrial Fibrillation (ReMeFa) is the first national multicenter registry with one-year clinical follow-up on the treatment of atrial fibrillation (AF) in newly diagnosed patients. Objective: To describe the demographics and treatment modalities for rhythm control (RC) strategy or heart rate (HR) control in patients with AF treated by cardiologists. A secondary objective was to prospectively evaluate the status of AF according to the chosen strategy; sinus rhythm in RC and mean ventricular rate at rest ≤ 80 bpm in HR, as well as the incidence of clinical outcomes at 12 month follow-up. Methods: ReMeFa was a multicenter, prospective, descriptive study. We included adults with documented AF. We excluded those with AF secondary to reversible causes, undergoing pulmonary vein ablation, pacemaker or defibrillator users, with a life expectancy of less than one year, or with physical or mental impediments to meet the protocol objectives. Data were collected at baseline and at 6 and 12 months. Results: We registered 1,201 subjects and 1,193 were eligible for evaluation: 40% were on RC strategy and 60% on HR control. In the RC strategy, the drugs most commonly used were class III antiarrhythmics (64%), beta-blockers (25%), and digoxin (24%). In HR control strategy, the drugs used were digoxin (69%), class III antiarrhythmics (59%), and beta-blockers (56%). Compared with those on HR control, patients in RC strategy were younger (64 ± 14 years), in sinus rhythm (55%) and with paroxysmal AF (60%) at baseline. Patients in HR control were older (68 ± 13 years), with non-paroxysmal AF (91%), valvular disease (42%), heart failure (35%), left ventricular dysfunction (33%), and diabetes (25%). At one year follow-up, a 3% incidence of ischemic stroke was observed in the HR control group, significantly higher than the 1% observed in the RC strategy (p = 0.041). Conclusions: ReMeFa registry results offer a current and comprehensive perspective on management strategies in Mexican patients with AF. The RC strategy provided better control of the arrhythmia as compared with the HR control strategy and it was associated with a lower rate of ischemic stroke. Nonetheless, current strategies of treatment of AF are not satisfactory.


REFERENCES

  1. European Heart Rhythm Association; European Association for Cardio- Thoracic Surgery, Camm AJ, Kirchhof P, et al. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429. S. Lara-Vaca, et al: Registro Mexicano de Fibrilación Auricular (ReMeFa) 59

  2. Greenlee RT, Vidaillet H. Recent progress in the epidemiology of atrial fibrillation. Curr Opin Cardiol. 2005;20(1):7-14.

  3. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of Atrial Fibrillation on the Risk of Death The Framingham Heart Study. Circulation. 1998;98(10):946-52.

  4. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation. J Am Coll Cardiol. 2003;41(10):1690-6.

  5. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-40.

  6. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33.

  7. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the anagement of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation. 2006;114(7):e257-354.

  8. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-327.

  9. Iturralde-Torres P, Lara-Vaca S, Cordero-Cabra A, et al. Diseño de un registro multicéntrico para evaluar control de ritmo contra control de la frecuencia en fibrilación auricular: Registro Mexicano de Fibrilación Auricular (ReMeFA). Arch Cardiol Mex. 2011;81(1):13-7.

  10. Le Heuzey JY, Breithardt G, Camm J, et al. The REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation (RecordAF Study): Design, Baseline Data, and Profile of Patients According to Chosen Treatment Strategy for Atrial Fibrillation. Am J Cardiol. 2010;105(5):687-93.

  11. Alam M, Bandeali SJ, Shahzad SA, Lakkis N. Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF): results of an international observational registry. Expert Rev Cardiovasc Ther. 2012;10(3):283-91.

  12. Go AS, Hylek EM, Phillips KA. Prevalence of diagnosed atrial fibrillation in adults: national implications of rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285(18):2370-5.

  13. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-25.

  14. Lévy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. Circulation. 1999;99(23):3028-35.

  15. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC Member Countries The Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26(22):2422-34.

  16. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11(4):423-34.

  17. Meiltz A, Zimmermann M, Urban P, Bloch A. Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace. 2008;10(6):674-80.

  18. Kerr C, Boone J, Connolly S, et al. Follow-up of atrial fibrillation: the initial experience of the Canadian Registry of Atrial Fibrillation. Eur Heart J. 1996;17 Suppl C:48-51.

  19. Goto S, Bhatt DL, Röther J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with therothrombosis. Am Heart J. 2008;156(5):855-63, 863.e2.

  20. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356(9244):1789-94.

  21. Barinagarrementeria Aldatz F. Actualidades en prevención secundaria de infarto cerebral por fibrilación auricular. Gac Med Mex. 2012; 148(3):248-56.

  22. Vargas Ruiz AG, Ramírez López AN, Medina Viramontes ME. Nuevos anticoagulantes: dabigatrán, rivaroxabán y apixabán. Gac Med Mex. 2012;148:257-64.

  23. Márquez MF, Iturralde-Torres P, Colín-Lizalde L, et al. Estudio electrofisiológico y ablación de actividad eléctrica anormal en venas pulmonares de pacientes con fibrilación auricular paroxística idiopática. Gac Med Mex. 2006;142(1):43-7.

  24. Roy D, Talajic M, Nattel S, et al.; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure (AF-CHF). N Engl J Med. 2008;358:2667-77.

  25. Pedersen OD, Bagger H, Keller N, Marchant B, Køber L, Torp-Pedersen C. Efficacy of Dofetilide in the Treatment of Atrial Fibrillation-Flutter in Patients With Reduced Left Ventricular Function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy. Circulation. 2001;104(3):292-6.

  26. The AFFIRM Investigator. Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Managemennt (AFFIRM) Study. Circulation. 2004;109(12):1509-13.




2020     |     www.medigraphic.com